Thyronamine

Thyronamine

SCHEMBL449823

NCCc1ccc(Oc2ccc(O)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 4/20 0.75
KDM4E B2RXH2 2/20 0.75
ALDH1A1 P00352 2/20 0.75
HTR1A P08908 2/20 0.75
ADRA2A P08913 2/20 0.75
SLC6A2 P23975 2/20 0.75
CYP2C19 P33261 1/20 0.75
HTR3A P46098 1/20 0.75
BACE1 P56817 1/20 0.75
L3MBTL1 Q9Y468 1/20 0.75
KMT2A Q03164 2/20 0.72
TDP1 Q9NUW8 2/20 0.72
BLM P54132 1/20 0.72
TAAR5 O14804 1/20 0.63
ESR1 P03372 2/20 0.58
ESR2 Q92731 2/20 0.58
MEN1 O00255 1/20 0.58
CALM1 P0DP23 1/20 0.50
MAOB P27338 1/20 0.50
LTA4H P09960 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6311979 0.89 TAAR1 (0.67) TAAR1KDM4EALDH1A1HTR1AADRA2A
SCHEMBL12804316 0.87 ESR1 (0.70) TAAR1KDM4EALDH1A1HTR1AADRA2A
Tyramine SCHEMBL134515 0.87 TAAR1 (1.00) TAAR1KDM4EALDH1A1HTR1AADRA2A
Tyramine SCHEMBL4111 0.87 TAAR1 (1.00) TAAR1KDM4EALDH1A1HTR1AADRA2A
Tyramine SCHEMBL30831107 0.87 TAAR1 (1.00) TAAR1KDM4EALDH1A1HTR1AADRA2A
Tyramine SCHEMBL30831130 0.87 TAAR1 (1.00) TAAR1KDM4EALDH1A1HTR1AADRA2A
Tyramine SCHEMBL1804993 0.84 TAAR1 (0.95) TAAR1KDM4EALDH1A1HTR1AADRA2A
Tyramine SCHEMBL7742928 0.84 TAAR1 (0.95) TAAR1KDM4EALDH1A1HTR1AADRA2A
Tyramine SCHEMBL2574990 0.84 TAAR1 (0.95) TAAR1KDM4EALDH1A1HTR1AADRA2A
Tyramine SCHEMBL2121 0.84 TDP1 (1.00) TAAR1KDM4EALDH1A1HTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4733383-A1 CULTURE MEDIUM AND BLOOD CELL CLONE, AND METHOD FOR PRODUCING SAME Japan Institute for Health Security (JP) 2026-04-29 EP claimed
WO-2024262610-A1 CULTURE MEDIUM AND BLOOD CELL CLONE, AND METHOD FOR PRODUCING SAME 国立研究開発法人国立国際医療研究センター 2024-12-26 WO claimed
US-20240101963-A1 SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2024-03-28 US claimed
EP-4271399-A1 ENHANCED DIFFERENTIATION OF BETA CELLS Vertex Pharmaceuticals Incorporated (US) 2023-11-08 EP claimed
US-20220265775-A1 COMPOSITIONS AND METHODS FOR TREATING PULMONARY EDEMA OR LUNG INFLAMMATION UNIV MINNESOTA (US) 2022-08-25 US claimed
WO-2022147056-A1 ENHANCED DIFFERENTIATION OF BETA CELLS VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-07-07 WO claimed
US-20210113120-A1 Vaginal Measurements Using a Vaginal Ring LIGALLI B.V. (NL) 2021-04-22 US claimed
EP-3773199-A1 VAGINAL MEASUREMENTS USING A VAGINAL RING Ligalli B.V. (NL) 2021-02-17 EP claimed
WO-2021021927-A1 COMPOSITIONS AND METHODS FOR TREATING PULMONARY EDEMA OR LUNG INFLAMMATION REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2021-02-04 WO claimed
WO-2019197486-A1 VAGINAL MEASUREMENTS USING A VAGINAL RING LIGALLI B.V. (NL) 2019-10-17 WO claimed
US-7321065-B2 Thyronamine derivatives and analogs and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-01-22 US claimed
WO-2007059039-A1 THYROXINE DERIVATIVES FOR PRECONDITIONING AGAINST STROKE OREGON HEALTH & SCIENCE UNIVERSITY (US) 2007-05-24 WO claimed
EP-1625111-A4 THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF UNIV CALIFORNIA (US) 2007-04-25 EP claimed
US-20060035980-A1 Thyronamine derivatives and analogs and methods of use thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-02-16 US claimed
EP-1625111-A2 THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-02-15 EP claimed
US-6979750-B1 Thyronamine derivatives and analogs and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-12-27 US claimed
US-20050267207-A1 Thyronamine derivatives and analogs and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-12-01 US claimed
US-20050096485-A1 Thyronamine derivatives and analogs and methods of use thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-05-05 US claimed
WO-2004093800-A2 THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2004-11-04 WO claimed
CN-1518469-A Dermatological preparations �����ɷ� 2004-08-04 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035980-A1 Thyronamine derivatives and analogs and methods of use thereof TPO, TSHR, THRB TAAR1 152/4885KDM4E 3632/4885ALDH1A1 2148/4885
US-20050096485-A1 Thyronamine derivatives and analogs and methods of use thereof TPO, TSHR, THRB TAAR1 198/4885KDM4E 3754/4885ALDH1A1 2156/4885
US-20240101963-A1 SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME IAPP, ALPG, PNLIP TAAR1 4310/4885KDM4E 4115/4885ALDH1A1 3569/4885
US-20050267207-A1 Thyronamine derivatives and analogs and methods of use thereof TPO, TSHR, THRB TAAR1 152/4885KDM4E 3632/4885ALDH1A1 2148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.